ARTICLE | Company News
FDA approves Galenica's PA21 for hyperphosphatemia
December 3, 2013 1:45 AM UTC
Galenica Ltd. (SIX:GALN) and its specialty pharma business Vifor Pharma Ltd. said FDA approved an NDA for Velphoro sucroferric oxyhydroxide ( PA21) to treat hyperphosphatemia in chronic kidney disease...